According to a recent survey from Oracle Health Sciences, 97% of trial professionals say newly adopted approaches will stay in use as we move beyond COVID-19.
Appili Therapeutics reports it has enrolled the last patient for its Phase III study of Avigan/Reeqonus (favipiravir), developed in alliance with AiPharma.
An epidemiologist from the healthcare data specialist offers perspective on how real-world data can help get to the heart of long-lasting COVID research.
With the launch of its Trialbee Honey technology, the company aims to bring together recruitment information from different sources for sweeter results.
According to the firm, infectious-disease research advancements could be applied to discovering treatments for millions of hepatitis patients globally.
The conference (with online and in-person content) is slated to gather professionals for deep conversations and lively collaboration on important topics.
The US agency plans to use the software firm’s Lighthouse technology to improve understanding of COVID-19 and other conditions in long-term care facilities.
Organizers of the drug delivery and packaging event have shared an industry report that reveals what is likely to push innovation forward in the future.
An expert from the IRB and study solutions firm explains how advanced analytics can lead to several benefits, including shortened trial startup timelines.
This month’s news on appointments, expansions, acquisitions and other events includes Nanoform, Elligo Health Research, Curavit, and other organizations.
According to the CEO of patient recruitment specialist SubjectWell, keeping up with the specialized needs of virtual studies calls for innovative thinking.
The pharma firm reports molnupiravir was shown to cut risk of hospitalization or death by 50% compared to placebos in a positive interim Phase III analysis.
A leader from Swift Medical describes the company’s skin and wound management technology, and how their tech empowers patient capture of vital information.
